PT  - JOURNAL ARTICLE
AU  - Man, Irene
AU  - Georges, Damien
AU  - Sankaranarayanan, Rengaswamy
AU  - Basu, Partha
AU  - Baussano, Iacopo
TI  - Building resilient cervical cancer prevention through gender-neutral HPV vaccination
AID  - 10.1101/2023.01.17.23284655
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.01.17.23284655
4099  - http://medrxiv.org/content/early/2023/01/18/2023.01.17.23284655.short
4100  - http://medrxiv.org/content/early/2023/01/18/2023.01.17.23284655.full
AB  - The COVID-19 pandemic has disrupted HPV vaccination programmes worldwide. Using an agent-based model, EpiMetHeos, recently calibrated to Indian data, we illustrate how shifting from girls-only (GO) to gender-neutral (GN) vaccination strategy could improve the resilience of cervical cancer prevention against disruption of HPV vaccination. In the base case of 5-year disruption with no coverage, shifting from GO to GN strategy under 60% coverage (before disruption) would increase the resilience, in terms of cervical cancer cases still prevented in the disrupted birth cohorts per 100,000 girls born, by 2.8-fold from 107 to 302 cases, and by 2.2-fold from 209 to 464 cases under 90% coverage. Furthermore, shifting to GN vaccination helped in reaching the WHO elimination threshold. Under GO vaccination with 60% coverage, the age-standardised incidence rate (ASIR) of cervical cancer in India in the long-term with vaccination decreased from 11.0 to 4.7 cases per 100,000 woman-years (above threshold), as compared to 2.8 cases (below threshold) under GN with 60% coverage and 2.4 cases (below threshold) under GN with 90% coverage. In conclusion, GN HPV vaccination is an effective strategy to improve the resilience to disruption of cancer prevention programmes and to enhance the progress towards cervical cancer elimination.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthe Bill & Melinda Gates Foundation (grant number: INV-039876)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The used datasets or databases regarding the IARC India HPV vaccine trial were obtained after a request. All other data are from public sources and are listed in the appendix (pp 6-14) indicated in the Data Availability Links section.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExternal researchers can make written requests to the IARC for sharing of data regarding the IARC India HPV vaccine trial. Requests will be assessed on a case-by-case basis in consultation with lead investigators and co-investigators. A brief analysis plan and data request will be required and reviewed by the investigators for approval of data sharing. When requests are approved, anonymised data will be sent electronically in password protected files. All data sharing will abide by rules and policies defined by the involved parties. Data sharing mechanisms will ensure that the rights and privacy of individuals participating in research will be protected at all times. Data are from public sources that are listed in the appendix (pp 6-14). http://ci5.iarc.fr https://www.ncdirindia.org/All_Reports/Report_2020/resources/NCRP_2020_2012_16.pdf https://www.aidsdatahub.org/sites/default/files/resource/national-bss-general-population-india-2006.pdf https://dhsprogram.com/ https://population.un.org/wpp/Download https://censusindia.gov.in/2011census/C-series/C-13.html